Search & Analyze

Orchid Pharma Ltd.

830.00−61.95 (−6.95%)

BSE · 30 Oct, 4:01 PM

: ₹4,988.74 Cr
: 575.67
: 6,944
: ₹900.00 - ₹830.00
: ₹1,142.65 - ₹471.30

Orchid Pharma Ltd. (ORCHPHARMA) share price closed at ₹830.00 on the BSE on Friday, October 30, 2026, down by 6.95% from its of ₹891.95. In that session ORCHPHARMA reached a of 900.00 and of 830.00. The for the session was 853.85. The stands at 967.61 and is at 811.71. Looking at , the stock ended the session in Downtrend.

Stock Overview

₹900.00

₹891.95

₹853.85

₹967.61

Price 14.22% below

₹811.71

Price 2.25% above

Key Fundamentals

: 4,988.74 Cr₹4.99 Thousand Crore
: 1.45
: 575.67
: 3.18
: 261.65
: 66.51 Cr₹66.51 Crore
: 0.00 %
Sector
Industry: Pharmaceuticals & Drugs
: 0.70
: 0.20

Industry Comparison

Ratio	Company	Sector
	575.67	44.77
	0.20	0.20
	3.18	4.61
	1.89	1.81
	0.00 %	0.11 %
Operating Margin	0.32 %	19.15 %

Sector figures are the median of 154 listed Healthcare companies.

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,778.25	38.91	4,26,661.74	0.90	1,995.07	-36.16%	16,198.71	11.88%	19.11
DIVI'S LAB. DIVISLAB	9,715.00	88.17	2,57,902.73	0.31	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,635.15	83.01	1,76,306.21	0.82	534.00	-9.64%	4,979.00	50.79%	19.27
LAURUSLABS LAURUSLABS	2,392.00	96.46	1,29,242.68	0.08	436.19	124.27%	2,206.37	33.44%	18.20
ZYDUSLIFE ZYDUSLIFE	1,244.00	27.50	1,24,089.48	0.08	990.20	-34.90%	8,017.00	21.96%	21.39
DR.REDDY'S DRREDDY	1,350.20	40.25	1,12,698.53	0.59	913.20	-31.69%	8,697.80	-1.48%	13.75
CIPLA LTD. CIPLA	1,380.00	38.48	1,11,488.55	0.94	851.51	-37.08%	7,403.93	-2.44%	16.00
Orchid Pharma Ltd. ORCHPHARMA	830.00	575.67	4,988.74	0.00	3.22	156.64%	304.17	15.57%	1.11

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	217.10	244.41	222.70	217.34	237.48	263.19	193.52	207.27	237.61	304.17
Expenses	188.18	211.91	192.36	190.98	209.50	268.83	195.00	205.70	210.74	290.17
	28.92	32.49	30.34	26.36	27.98	-5.64	-1.48	1.56	26.86	14.00
	13.32%	13.29%	13.62%	12.13%	11.78%	-2.14%	-0.76%	0.75%	11.31%	4.60%
	13.36	7.57	7.52	8.49	3.90	11.57	10.77	-1.50	7.88	1.83
Interest	3.47	3.50	3.33	3.80	3.92	2.29	3.73	3.18	3.09	2.23
	8.42	8.44	8.63	8.61	8.87	10.54	8.90	9.03	8.87	10.95
	29.84	29.20	27.24	20.78	22.26	-5.69	-5.72	-12.61	23.78	3.30
	-10.45%	-0.53%	0.00%	0.00%	-0.18%	0.00%	0.00%	0.00%	0.01%	2.18%
	32.96	29.35	27.24	20.78	22.29	-5.69	-5.72	-12.61	23.78	3.22
	6.50	5.79	5.37	4.10	4.40	-0.95	-1.13	-2.49	4.69	0.54

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	559.56	665.90	819.37	1,397.61	1,232.78
	559.56	665.90	819.37	1,397.61	1,232.78
EXPENDITURE :
Increase/Decrease in Stock	-27.06	-21.48	-43.89	-21.95	71.38
Raw Material Consumed	340.62	406.10	528.35	915.30	773.08
Power & Fuel Cost	52.74	61.26	62.92	100.07	89.62
Employee Cost	63.28	65.35	69.64	109.23	117.65
Other Manufacturing Expenses	32.88	35.55	39.75	61.95	61.31
General and Administration Expenses	13.03	14.26	22.22	26.79	26.25
Selling and Distribution Expenses	22.26	14.34	23.86	36.58	27.99
Miscellaneous Expenses	7.22	6.22	5.73	31.79	61.61
	504.98	581.60	708.58	1,259.76	1,228.89
Operating Profit (Excl OI)	54.58	84.30	110.79	137.85	3.89
	9.00	19.43	31.13	38.95	66.46
	63.58	103.73	141.92	176.80	70.35
Interest	33.46	32.90	16.74	13.25	9.34
PBDT	30.13	70.82	125.18	163.55	61.01
	87.02	54.79	33.24	42.02	43.25
Profit Before Taxation & Exceptional Items	-56.90	16.04	91.95	121.53	17.76
Exceptional Income / Expenses		39.21			-7.33
	-56.90	55.25	91.95	121.53	10.43
Provision for Tax			-3.12	-9.64	-0.19
	-56.90	55.25	95.06	131.17	10.62
Extra items				0.00	0.00
Share of Associate	-3.52	-2.15	-2.90	3.90	-0.66
Consolidated Net Profit	-1.95	46.32	92.17	135.07	9.96
Profit Balance B/F	-2,313.84	-2,314.33	-2,268.24	-2,176.52	-1,803.35
Appropriations	-2,315.79	-2,268.01	-2,176.07	-2,041.45	-1,793.39
	-0.48	11.35	18.17	88.29	6.51
Adjusted EPS	-0.48	11.35	18.17	88.29	6.51

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	40.82	40.82	50.72	15.30	15.30
Share Warrants & Outstandings				44.59	44.59
Total Reserves	606.56	647.83	1,118.75	1,494.05	1,504.42
Reserve excluding Revaluation Reserve	606.56	647.83	1,118.75	1,494.05	1,504.42
Revaluation reserve			0.00
	647.38	688.65	1,169.47	1,553.93	1,564.31
Secured Loans	110.84	40.09	0.22	0.03	184.74
Unsecured Loans	97.32	108.75	120.21	10.00
Deferred Tax Assets / Liabilities	3.23	3.23		-0.10	-0.29
Other Long Term Liabilities			0.37	0.04	4.72
Long Term Provisions	11.01	12.60	3.63	4.70	13.45
Total Non-Current Liabilities	222.40	164.67	124.43	14.67	202.62
Trade Payables	167.68	174.37	229.58	336.16	346.71
Other Current Liabilities	47.25	53.09	14.27	26.60	55.81
Short Term Borrowings	22.84	140.95	14.05	143.04	87.89
Short Term Provisions	3.01	3.49	2.08	2.86	0.80
Total Current Liabilities	240.78	371.89	259.97	508.66	491.21
Total Liabilities	1,110.56	1,225.21	1,553.87	2,077.26	2,258.13
Gross Block	1,176.39	1,220.56	1,300.94	1,498.65	1,516.87
Less: Accumulated Depreciation	592.68	647.47	680.71	790.90	824.73
	583.70	573.09	620.23	707.75	692.13
	9.78	46.46	16.39	64.49	340.52
Non Current Investments	45.49	44.44	45.82	59.90	66.97
Long Term Investment	45.49	44.44	45.82	59.90	66.97
Long Term Loans & Advances	73.93	60.20	66.38	131.45	156.45
Other Non Current Assets	0.01		0.02	0.02	0.02
Total Non-Current Assets	712.91	724.20	763.12	979.84	1,329.16
Inventories	172.66	228.74	264.23	457.37	372.31
Sundry Debtors	170.57	215.19	195.55	353.05	381.35
Cash and Bank	8.06	30.63	266.57	200.63	83.52
Other Current Assets	13.01	3.95	7.05	10.87	16.77
Short Term Loans and Advances	20.07	22.50	57.36	75.51	75.02
Total Current Assets	384.36	501.01	790.75	1,097.43	928.97
Net Current Assets (Including Current Investments)	143.58	129.12	530.78	588.76	437.76
Total Assets	1,110.56	1,225.21	1,553.87	2,077.26	2,258.13
	42.88	42.48	56.97	18.24	24.51
Total Debt	267.95	331.35	134.48	153.34	301.44
	158.61	168.72	230.58	986.56	993.34
Adjusted Book Value	158.61	168.72	230.58	986.56	993.34

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	-1.95	46.32	89.05	121.53	10.43
Adjustment	36.77	51.38	44.15	40.32	41.98
Changes In working Capital	59.57	-79.06	-7.84	-95.33	70.88
Cash Flow after changes in Working Capital	94.38	18.64	125.36	66.52	123.28
Cash Flow from Operating Activities	92.47	18.34	125.99	51.37	125.64
Cash Flow from Investing Activities	112.94	-31.21	-312.03	-36.48	-276.88
Cash Flow from Financing Activitie	-216.80	31.17	167.04	2.46	137.14
Net Cash Inflow / Outflow	-11.39	18.29	-19.00	17.34	-14.10
Opening Cash & Cash Equivalents	15.69	4.31	22.60	3.83	21.18
Closing Cash & Cash Equivalent	4.31	22.60	3.60	21.18	7.07

Ratios

Valuation

575.67

3.18

78.29

5.29

1.45

261.65

Profitability

0.70

1.11

0.49

0.32

0.86

Leverage & Liquidity

0.20

1.89

2.12

Returns

0.00

0.57

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	69.84	69.84	69.84	69.84	69.84	69.84	69.84	69.84	69.84	74.45
	20.35	20.23	21.52	22.79	20.83	20.60	20.56	21.12	21.56	18.37
	9.81	9.93	8.64	7.38	9.34	9.57	9.60	9.05	8.61	7.18
	30.16	30.16	30.16	30.16	30.16	30.16	30.16	30.16	30.16	25.55
No. of Shareholders	34,695	36,363	34,158	34,303	39,827	38,155	35,709	35,118	33,433	33,790

Mutual Funds Invested(26)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 23 active funds hold 16.88% in Orchid Pharma Ltd., contributing to ₹1.01K Cr of holdings

Fund				As of
QU Quant Small Cap Fund - Growth - Direct PlanSmall cap Fund	345.55	0.97	34,65,947	Sep '26
UT UTI Value Fund - Growth - Direct PlanEquity - Value Fund	118.54	1.31	11,88,926	Sep '26
IN Invesco India Contra Fund - Growth - Direct PlanEquity - Contra Fund	98.78	0.51	9,90,763	Sep '26
KO Kotak Multi Asset Allocation Fund - Growth - Direct PlanHybrid - Multi Asset Allocation	94.01	0.62	9,42,962	Sep '26
UT UTI Small Cap Fund - Growth - Direct PlanSmall cap Fund	50.84	0.97	5,09,966	Sep '26
KO Kotak Special Opportunities Fund - Growth - Direct PlanEquity - Thematic Fund - Other	48.63	2.53	4,87,811	Sep '26
IN Invesco India Smallcap Fund - Growth - Direct PlanSmall cap Fund	45.38	0.28	4,55,183	Sep '26
ID Bandhan Small Cap Fund - Growth - Direct PlanSmall cap Fund	45.30	0.13	4,54,372	Sep '26
KO Kotak Consumption Fund - Growth - Direct PlanConsumption	28.51	1.72	2,86,000	Sep '26
KO Kotak Multi Cap Fund - Growth - Direct PlanMulti Cap Fund	26.35	0.09	2,64,308	Sep '26

Corporate Actions

Showing: All

Date	Type	Details
2026-10-15	Board Meeting	Inter alia, to consider and evaluate various options for raising funds by way of issue of equity shares or any other eligible securities or instruments, including fully or partly convertible debentures, or through a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares or other eligible securities, by way of qualified institutions placement/ preferential issue/ private placement, public issue of equity shares and/or debt securities or through any other permissible mode, or any combination thereof, as may be considered appropriate, subject to such statutory and regulatory approvals as may be required, including the approval of the members of the Company, wherever applicable, and such other approvals, permissions and consents as may be necessary
2026-09-08	AGM
2026-08-11	Board Meeting	Quarterly Results

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Orchid Pharma Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

9 members across the board and senior leadership

Ram Gopal Agarwal

Chairman

₹40,000

Mar '26

Manish Dhanuka

Managing Director

₹3.29 Cr

Mar '26

Mridul Dhanuka

Whole Time Director

₹3.29 Cr

Mar '26

Arjun Dhanuka

Non Independent & Non Executive Director

₹2.10 L

Mar '26

Dharam Vir

Non Executive Independent Director

₹2.60 L

Mar '26

Manoj Kumar Goyal

Non Executive Independent Director

₹2.80 L

Mar '26

Shubha Singh

Non Executive Independent Director

₹2.20 L

Mar '26

Tanu Singla

Non Executive Independent Director

₹2.30 L

Mar '26

Kapil Dayya

Company Secretary & Compliance Officer

—

ORCHPHARMA Latest News

News

5 of 5 articles

COMPANY26 Oct 2026 · 11:18

Orchid Pharma signs licensing, supply agreement with Libra

Designed as a carbapenem-sparing option, Exblifep targets serious hospital infections driven by ESBL-producing Gram-negative bacteria

EQUITY8 Jul 2026 · 09:26

Orchid Pharma zooms on signing licensing and supply agreement with Pharmasyntez

Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form

COMPANY8 Jul 2026 · 09:16

Orchid Pharma signs licensing and supply agreement with Pharmasyntez

Under the agreement, Pharmasyntez will hold the exclusive rights to register and commercialize Exblifep in Russia, with Orchid supplying the finished dosage form

EQUITY26 May 2026 · 16:52

Orchid Pharma informs about investor presentation

EQUITY25 May 2026 · 19:47

Orchid Pharma reports Profit after tax of Rs 306.03 Mln, in the March 2026 quarter

Orchid Pharma Ltd.

Stock Overview

Price chart

Peer Comparison

Quarterly Results

Profit & Loss

Balance Sheet

Cash Flow

Ratios

Valuation

Profitability

Leverage & Liquidity

Returns

Shareholding Pattern

Mutual Funds Invested(26)

Corporate Actions

Insider Trading

Sector Overview

Company Profile

Key Management

ORCHPHARMA Latest News

News